Drugs / NSC-CRAd-S-pk7
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06169280 | Jun 2025 → Dec 2029 | malignant glioma | Northwestern University | Suspended | No outcome recorded |
| Phase 1 | NCT05139056 | May 2023 → Aug 2026 | — | City of Hope Medical Center | Suspended | No outcome recorded |
| Phase 1 | NCT03072134 | Apr 2017 → Apr 2020 | anaplastic astrocytoma, anaplastic oligoastrocytoma, anaplastic oligodendroglioma, brain cancer +1 | Northwestern University | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NSCCRAd-S-pk7 | “We examined the safety and activity of NSC-CRAd-S-pk7, an engineered oncolytic adenovirus delivered by neural stem cells (NSCs), in patients with newly diagnosed high-grade glioma.” PMID 34214495 ↗ Jun 20213“This phase I trial studies the safety of giving multiple intracerebral doses of NSC-CRAd-S-pk7 to treat patients with glioblastoma at first recurrence.” NCT05139056 ↗ “intracavitary (ICT) administered neural stem cell-expressing CRAd-S-pk7 (NSCCRAd-S-pk7)” NCT05139056 ↗ |
| Modality | Cell therapy | “NSC-CRAd-S-pk7 consists of neural stem cells that can target glioblastoma cells and carry a virus” NCT05139056 ↗ |
| Route | Other | “Direct intra-tumoral injection of study product (NSC-CRAd-S-p7) will be done after resection but prior to closure.” NCT03072134 ↗ |